Clinical trials in sub-Saharan Africa and established standards of care: a systematic review of HIV, tuberculosis, and malaria trials.

CONTEXT The minimum standard of care required for participants in clinical trials conducted in resource-poor settings is a matter of controversy; international documents offer contradictory guidance. OBJECTIVE To determine whether recently published trials conducted in sub-Saharan Africa met standards of care consistent with best current clinical standards for human immunodeficiency virus (HIV) treatment, tuberculosis treatment, and malaria prevention. DATA SOURCES Trials published during or after January 1998 that were indexed at the time of the MEDLINE and Cochrane Controlled Trials Register Search (November 20, 2003). STUDY SELECTION All randomized clinical trials that were conducted in sub-Saharan Africa in 3 clinical domains: HIV disease, tuberculosis treatment, and malaria prophylaxis. DATA EXTRACTION To establish criteria for best current standards of care, evidence from the literature and published guidelines accepted for well-resourced settings were analyzed; the actual care offered in the trial was then compared with these standards. DATA SYNTHESIS A total of 128 eligible articles described data from 73 different randomized clinical trials. Only 12 trials (16%) provided care that met guidelines to both intervention and control patients. Only 1 of the 34 trials that enrolled patients with HIV disease provided antiretroviral treatment that conformed to guidelines. Conversely, all tuberculosis treatment trials (n = 13, including 3 for HIV-infected patients) provided tuberculosis therapy that conformed to guidelines. Twenty-one (72%) of 29 malaria prophylaxis trials tested interventions that met guidelines, but only 3 (10%) used any active prophylactic intervention in the control group. Of the 59 trials (81%) that reported on the process of ethical review, all were reviewed by a host African institution and 64% were additionally reviewed by an institution in a developed country. CONCLUSIONS Rates of adherence to established clinical guidelines of care in randomized clinical trials of HIV treatment, tuberculosis treatment, and malaria prophylaxis varied considerably between disease categories. In determining clinical standards for trials in sub-Saharan Africa, researchers and ethics committees appear to take the local level of care into account.

[1]  David M Kent,et al.  New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  D. Hoover,et al.  Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial , 2003, The Lancet.

[3]  D. Kent,et al.  Testing Therapies Less Effective than the Best Current Standard: Ethical Beliefs in an International Sample of Researchers , 2003, The American journal of bioethics : AJOB.

[4]  John L Sullivan,et al.  A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. , 2003, The Journal of infectious diseases.

[5]  W. Blattner,et al.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. , 2002 .

[6]  John P A Ioannidis,et al.  Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research , 2002, BMJ : British Medical Journal.

[7]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[8]  R. Levine,et al.  The need to revise the Declaration of Helsinki. , 1999, The New England journal of medicine.

[9]  J. Curran,et al.  Science, ethics, and future of research into maternal-infant transmission of HIV-1 , 1999, The Lancet.

[10]  J. Karon,et al.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial , 1999, The Lancet.

[11]  J. Karon,et al.  Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial , 1999, The Lancet.

[12]  H. Coovadia,et al.  Short course antiretroviral regimens to reduce maternal transmission of HIV , 1999, BMJ.

[13]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[14]  J. Montaner,et al.  The effects of lamivudine treatment on HIV‐1 disease progression are highly correlated with plasma HIV‐1 RNA and CD4 cell count , 1998, AIDS.

[15]  B. Bloom The Highest Attainable Standard: Ethical Issues in AIDS Vaccines , 1998, Science.

[16]  H. Varmus,et al.  Ethical complexities of conducting research in developing countries. , 1997, The New England journal of medicine.

[17]  P. Lurie,et al.  Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. , 1997, The New England journal of medicine.

[18]  M. Angell The ethics of clinical research in the Third World. , 1997, The New England journal of medicine.

[19]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[20]  Douglas D. Richman,et al.  Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .

[21]  C. Lengeler,et al.  Impact of permethrin impregnated bednets on child mortality in Kassena‐Nankana district, Ghana: a randomized controlled trial , 1996, Tropical medicine & international health : TM & IH.

[22]  C. Curtis Editorial: Impregnated bednets, malaria control and child mortality in Africa , 1996, Tropical medicine & international health : TM & IH.

[23]  R. Snow,et al.  Insecticide‐treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast , 1996, Tropical medicine & international health : TM & IH.

[24]  S. Teutsch,et al.  The effectiveness of insecticide-impregnated bed nets in reducing cases of malaria infection: a meta-analysis of published results. , 1995, The American journal of tropical medicine and hygiene.

[25]  M. C. Thomson,et al.  Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme , 1995, The Lancet.

[26]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[27]  R. Schooley,et al.  Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference , 1993 .

[28]  P. Phillips-Howard,et al.  Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa , 1993, The Lancet.

[29]  S. Lindsay,et al.  The effect of insecticide-treated bed nets on mortality of Gambian children , 1991, The Lancet.

[30]  L. Pang,et al.  DOXYCYCLINE PROPHYLAXIS FOR FALCIPARUM MALARIA , 1987, The Lancet.

[31]  F. Wit,et al.  Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial , 1997 .

[32]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .